By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cancer Genetics, Inc. 

Meadows Office Complex
201 Route 17 North

2nd Floor
Rutherford  New York  07070  U.S.A.
Phone: 201-528-9200 Fax: 201-528-9201



Company News
Cancer Genetics (CGIX) And ApoCell, Inc. Announce Partnership Focused On Transforming Cancer Profiling & Therapy Selection Leveraging Proprietary, High-Performance, Liquid Biopsy Platform For Rare Cell Capture And Detection 9/26/2016 7:38:55 AM
Cancer Genetics (CGIX) Strengthens Position As A Leader In Myeloid Cancer Diagnosis And Management Receiving New York State Approval For Focus: Myeloid, A Targeted NGS Panel For Improved Diagnosis, Risk Stratification, And Therapy Selection Of Patients With Myeloid Cancers 8/17/2016 7:45:41 AM
Cancer Genetics (CGIX) Reports Second Quarter 2016 Financial Results And Provides Company Updates 8/10/2016 10:49:21 AM
Cancer Genetics (CGIX) To Report Second Quarter Earnings On Wednesday, August 10 8/2/2016 8:09:49 AM
Cancer Genetics (CGIX) Selected By H3 Biomedicine To Provide Biomarker Discovery And Testing For A Global Drug Development Program In Hematologic Cancers 7/18/2016 8:03:16 AM
Cancer Genetics (CGIX) Receives New York State Approval For Focus::CLL, A Unique NGS Panel For Chronic Lymphocytic Leukemia, Reinforcing The Company’s Market-Leading Position In The Diagnosis And Management Of B-Cell Cancers 6/30/2016 1:51:21 PM
Cancer Genetics (CGIX) Expands Its Immuno-Oncology Franchise With The Addition Of The FDA-Approved VENTANA PD-L1 (SP142) Assay As A Complementary Diagnostic Test For TECENTRIQ 6/29/2016 6:51:24 AM
Cancer Genetics (CGIX) Names Healthcare Technology Industry Veteran John Jay Roberts As COO And Executive Vice President Of Finance 6/27/2016 9:58:14 AM
Cancer Genetics (CGIX) And Sayre Therapeutics Announce Distribution Agreement To Commercialize CGI’s Proprietary FDA-Cleared Tissue Of Origin (TOO) Test Throughout India And South Asia 6/23/2016 7:36:45 AM
Cancer Genetics (CGIX) To Present At The 2016 LD Micro Invitational Investor Conference 6/7/2016 1:53:01 PM